New combo attack on returning prostate cancer shows promise in early trial

NCT ID NCT05496959

Ongoing Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. The goal is to see if the combination delays cancer progression more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium Lu-177 PNT2002 (a radioactive drug that targets prostate cancer cells)
What this could lead to: If it works, this combination could offer a more effective way to control prostate cancer that has returned in a few spots, potentially delaying further spread.
What could go wrong: This is a mid-stage trial with only 93 people, so results may not apply to everyone. The treatment involves radiation, which can cause side effects like fatigue or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OLIGOMETASTATIC PROSTATE CARCINOMA PROSTATE ADENOCARCINOMA RECURRENT PROSTATE ADENOCARCINOMA STAGE IVB PROSTATE CANCER AJCC V8

Contacts and locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.